Delhi, India -- (SBWire) -- 11/04/2010 -- "According to Imarc’s latest research report, “Global Biopharmaceutical Market Report (2010-2015)”, the global Monoclonal Antibodies market was worth over US$ 31 billion in 2009, thus accounting for nearly 34% of the total global biopharmaceutical sales. Imarc expects this market to exceed US$ 79 billion by 2015. This represents an incremental growth of US$ 48 billion during 2009 and 2015, representing more than 64% of the total global biopharmaceutical market growth during the period.
Findings in the report show that in 2009, eight Monoclonal Antibodies marketed during the year achieved sales worth more than US$ 1 Billion; and out of these, two were amongst the top ten selling pharmaceutical products. By 2016, six of the world’s top ten selling pharmaceutical products are expected to be Monoclonal Antibodies.
The report comprehensively investigates the factors that will drive the sales of Monoclonal Antibodies in the next five years and infers that a rich pipeline coupled with the high specificity and ability of Monoclonal Antibodies to attack targets beyond the reach of small molecule drugs will be the key strengths driving their growth in the next five years.
Table of Contents
1. Market Definitions & Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2009)
5.1.2 Market Forecasts (2010-2015)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2009)
5.2.2 Market Forecasts (2010-2015)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2005-2009)
5.4.1.2 Market Forecasts (2010-2015)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2005-2009)
5.4.2.2 Market Forecast (2010-2015)
5.4.3 Purified Proteins
5.4.3.1 Current Performance (2005-2009)
5.4.3.2 Market Forecast (2010-2015)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2009)
6.1.2 Market Segmentation by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Performance of Top Players
6.1.4 Market Forecasts (2010-2015)
6.2 Canada
6.2.1 Market Performance (2005-2009)
6.2.2 Market Segmentation by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.3 Performance of Top Players
6.2.4 Market Forecasts (2010-2015)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2009)
7.1.2 Market Segmentation by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Performance of Top Players
7.1.4 Market Forecasts (2010-2015)
7.2 Brazil
7.2.1 Market Performance (2005-2009)
7.2.2 Market Segmentation by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Performance of Top Players
7.2.4 Market Forecasts (2010-2015)
7.3 Argentina
7.3.1 Market Performance (2005-2009)
7.3.2 Market Segmentation by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Performance of Top Players
7.3.4 Market Forecasts (2010-2015)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2009)
8.1.2 Market Segmentation by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Performance of Top Players
8.1.4 Market Forecasts (2010-2015)
8.2 France
8.2.1 Market Performance (2005-2009)
8.2.2 Market Segmentation by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Performance of Top Players
8.2.4 Market Forecasts (2010-2015)
8.3 Italy
8.3.1 Market Performance (2005-2009)
8.3.2 Market Segmentation by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Performance of Top Players
8.3.4 Market Forecasts (2010-2015)
8.4 Spain
8.4.1 Market Performance (2005-2009)
8.4.2 Market Segmentation by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Performance of Top Players
8.4.4 Market Forecasts (2010-2015)
8.5 UK
8.5.1 Market Performance (2005-2009)
8.5.2 Market Segmentation by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Performance of Top Players
8.5.4 Market Forecasts (2010-2015)
8.6 Russia
8.6.1 Market Performance (2005-2009)
8.6.2 Market Segmentation by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Performance of Top Players
8.6.4 Market Forecasts (2010-2015)
8.7 Turkey
8.7.1 Market Performance (2005-2009)
8.7.2 Market Segmentation by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Performance of Top Players
8.7.4 Market Forecasts (2010-2015)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2009)
9.1.2 Market Segmentation by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Performance of Top Players
9.1.4 Market Forecasts (2010-2015)
9.2 China
9.2.1 Market Performance (2005-2009)
9.2.2 Market Segmentation by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Performance of Top Players
9.2.4 Market Forecasts (2010-2015)
9.3 Australia
9.3.1 Market Performance (2005-2009)
9.3.2 Market Segmentation by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Performance of Top Players
9.3.4 Market Forecasts (2010-2015)
9.4 South Korea
9.4.1 Market Performance (2005-2009)
9.4.2 Market Segmentation by Class
9.4.2.1 Recombinant Proteins
9.4.2.2 Monoclonal Antibodies
9.4.2.3 Purified Proteins
9.4.3 Performance of Top Players
9.4.4 Market Forecasts (2010-2015)
9.5 India
9.5.1 Market Performance (2005-2009)
9.5.2 Market Segmentation by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Performance of Top Players
9.5.4 Market Forecasts (2010-2015)
9.6 Indonesia
9.6.1 Market Performance (2005-2009)
9.6.2 Market Segmentation by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Performance of Top Players
9.6.4 Market Forecasts (2010-2015)
To get the full version of “Global Biopharmaceutical Market Report (2010-2015)” please get in touch with us by emailing us at sales@imarcgroup.com or by calling us on +91-11-43095788
Monoclonal Antibodies: A Gold Rush Among Drug Manufacturers
"The commercial success achieved by Monoclonal Antibodies in the last five years cannot be matched by any other drug class. Imarc expects this robust growth to continue in the next five years, driven primarily by a rich late stage pipeline and a strong demand from patients having high unmet therapeutic needs."